Product Description
We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions. (Sourced from: https://www.daxor.com)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daxor
Company Location: NEW YORK NY 10118
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BVAC19 | N/A |
Completed |
Acute Respiratory Distress Syndrome|COVID-19|Sepsis|Respiratory Distress Syndrome, Newborn|Acute Lung Injury |
2023-04-09 |
|
| BVA for inpatient HF | N/A |
Completed |
Heart Failure, Acute |
2022-12-31 |
|
| CLIN06477 | N/A |
Terminated |
Heart Failure, Acute |
2022-12-27 |
|
| MOVE-HF | N/A |
Completed |
Heart Failure |
2022-07-15 |